Lotus Eye Hospital Institute Ltd vs Pramodini Medicare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Lotus Eye Hospital & Institute Ltd is ₹ 112.75 as of 23 Oct 15:30 . The P/E Ratio of Lotus Eye Hospital & Institute Ltd changed from 0 on March 2022 to 0 on March 2026 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Pramodini Medicare Ltd changed from 0 on March 2022 to 0 on March 2026 . This represents a CAGR of 0.0% over 5 years The Market Cap of Lotus Eye Hospital & Institute Ltd changed from ₹ 0 crore on March 2022 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Pramodini Medicare Ltd changed from ₹ 0 crore on March 2022 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 5 years The revenue of Lotus Eye Hospital & Institute Ltd for the Jun '26 is ₹ 17.27 crore as compare to the Mar '26 revenue of ₹ 14.09 crore. This represent the growth of 22.57% The revenue of Pramodini Medicare Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Lotus Eye Hospital & Institute Ltd for the Jun '26 is ₹ 3.15 crore as compare to the Mar '26 ebitda of ₹ 0.95 crore. This represent the growth of 231.58% The ebitda of Pramodini Medicare Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Lotus Eye Hospital & Institute Ltd changed from ₹ 0.62 crore to ₹ 0.61 crore over 9 quarters. This represents a CAGR of -0.72% The net profit of Pramodini Medicare Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The Dividend Payout of Lotus Eye Hospital & Institute Ltd changed from 66.24 % on March 2021 to 0 % on March 2026 . This represents a CAGR of -100.00% over 6 yearsThe Dividend Payout of Pramodini Medicare Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Lotus Eye Hospital & Institute Ltd

Lotus Eye Hospital & Institute Limited, a trust hospital, was originally incorporated as 'Kalaivani Health Centre Pvt.
Limited' on 14 March, 1997.
The name of the Company was changed to 'Lotus Eye Care Hospital Pvt.
Limited' on 23 January, 2006 and later on, the Company was converted into a Public Limited Company on October 16, 2007 and subsequently, the name was changed to Lotus Eye Hospital & Institute Limited on April 12, 2013. Founded in 1990 by renowned ophthalmic surgeon late Dr. S.K. Sundaramoorthy, the Company operates 9 Eye Care centers in Tamil Nadu and Kerala: 7 Centres in Tamil Nadu: Coimbatore (Peelamedu, RS puramand Saravanampatti), Salem , Tirupur Mettupalayam and Karur. 2 Centresin Kerala: Kochi and Mulanthuruthy. Lotus Eye Care Hospital is the state of art eye care hospital group functioning in South India with specialization in super-specialty service related to eye care.

About Pramodini Medicare Ltd

Pramodini Medicare Limited was originally incorporated on September 12, 2000 as 'Pramodini Medicare Private Limited' with the Registrar of Companies, Andhra Pradesh.
Thereafter, the status of the Company changed to public limited Company and the name was changed to 'Pramodini Medicare Limited' vide fresh certificate of incorporation dated November 12, 2025. Company was originally incorporated in the year 2000 with the objective to provide diagnostic services.
The Company provide a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges across tier I, tier II and tier III cities throughout India. Diagnostic services include a comprehensive range of offerings: (i) 'Radiology' which covers Magnetic Resonance Imaging (MRI), Computed Tomography (CT scan), X- ray, Ultrasound with colour doppler, Mammography, DEXA Scan and Intervention Radiology, (ii) 'Clinical Laboratory' which includes Haematology, Micro-Biology, Immunology, Pathology & Bio-Chemistry and (iii) 'Nuclear Medicine' which includes PET-CT (Positron Emission Tomography-Computed Tomography), SPECT (Single Photon Emission Computed Tomography) and Nuclear therapy.

FAQs for the comparison of Lotus Eye Hospital & Institute Ltd and null

Which company has a larger market capitalization, Lotus Eye Hospital & Institute Ltd or Pramodini Medicare Ltd?

Market cap of Lotus Eye Hospital & Institute Ltd is 234 Cr while Market cap of Pramodini Medicare Ltd is 239 Cr

What are the key factors driving the stock performance of Lotus Eye Hospital & Institute Ltd and Pramodini Medicare Ltd?

The stock performance of Lotus Eye Hospital & Institute Ltd and Pramodini Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Lotus Eye Hospital & Institute Ltd and Pramodini Medicare Ltd?

As of October 25, 2026, the Lotus Eye Hospital & Institute Ltd stock price is INR ₹112.75. On the other hand, Pramodini Medicare Ltd stock price is INR ₹108.65.

How do dividend payouts of Lotus Eye Hospital & Institute Ltd and Pramodini Medicare Ltd compare?

To compare the dividend payouts of Lotus Eye Hospital & Institute Ltd and Pramodini Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.